In an era of increasing antimicrobial resistance, there is a growing need for new antimicrobial agents with novel mechanisms of action. Tigecycline is an agent derived from tetracycline antimicrobials with a broad spectrum of activity, including some drug-resistant pathogens. In addition to clinical trial data, early off-label and in vitro experiences indicate a potential role for tigecycline in the management of certain infections with drug-resistant isolates. This is especially noteworthy given the continuing emergence of resistant bacteria for which there are limited antimicrobial options available. Emergence of resistance to tigecycline is currently uncommon but has been encountered clinically. Further studies are needed to determine the ultimate role of tigecycline for treating serious infections with drug-resistant pathogens.
Debra A. Goff, The Ohio State University Medical Center, Department of Pharmacy, 368 Doan Hall, Columbus, OH 43215, USA. E-Mail: email@example.com
Expert Rev Anti Infect Ther. 2008;6(5):557-567. © 2008 Expert Reviews Ltd.
No writing assistance was utilized in the production of this manuscript.
Cite this: Establishing the Role of Tigecycline in an era of Antimicrobial Resistance - Medscape - Oct 01, 2008.